Course Provider
Learning Objectives
Participants will integrate recent advances and available clinical data to optimally select and sequence agents for the care of patients with HER2-negative metastatic breast cancer.
Participants will select and sequence HER2-targeted agents in the first and subsequent lines of treatment of HER2-positive metastatic breast cancer.
Participants will discuss barriers to clinical trial access for patients with metastatic breast cancer and outline potential solutions.